Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Venetoclax combination therapies in AML

Andrew Wei • 15 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Gilteritinib Ivosidenib Venetoclax

Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses viable options for combining venetoclax with targeted therapies in acute myeloid leukemia (AML). Specifically outlined is venetoclax combined with ivosidenib, an IDH1 inhibitor, as well as with gilteritinib, a FLT3 inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrew Wei

New approaches to target TP53-mutated AML: the ADAPT trial
10:05
New approaches to target TP53-mutated AML: the ADAPT trial
Andrew Wei • 20 Sep 2026
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
18:47
Insights into established therapies in AML: OPTI-AML & the future of combination therapy
Andrew Wei et al. • 20 Sep 2026
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
16:15
Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies
Andrew Wei et al. • 19 Sep 2025
Current challenges in clinical genomics
Current challenges in clinical genomics
Andrew Wei et al. • 29 Sep 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals